Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on December 8, 2008

Circulation. 2008
Published online before print December 8, 2008, doi: 10.1161/CIRCULATIONAHA.108.788604
A more recent version of this article appeared on December 16, 2008
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
118/25/2773    most recent
CIRCULATIONAHA.108.788604v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stevenson, W. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stevenson, W. G.
Related Collections
Right arrow Ablation/ICD/surgery
Right arrow Arrhythmias, clinical electrophysiology, drugs
Right arrow Chronic ischemic heart disease
Right arrowRelated Article

Submitted on April 24, 2008
Accepted on August 22, 2008

Irrigated Radiofrequency Catheter Ablation Guided by Electroanatomic Mapping for Recurrent Ventricular Tachycardia After Myocardial Infarction. The Multicenter Thermocool Ventricular Tachycardia Ablation Trial

William G. Stevenson MD*, David J. Wilber MD, Andrea Natale MD, Warren M. Jackman MD, Francis E. Marchlinski MD, Timothy Talbert MD, Mario D. Gonzalez MD, Seth J. Worley MD, Emile G. Daoud MD, Chun Hwang MD, Claudio Schuger MD, Thomas E. Bump MD, Mohammad Jazayeri MD, Gery F. Tomassoni MD, Harry A. Kopelman MD, Kyoko Soejima MD, Hiroshi Nakagawa MD, for the Multicenter Thermocool VT Ablation Trial Investigators

From the Brigham and Women's Hospital, Boston, Mass (W.G.S., K.S.); Loyola University Medical Center, Maywood, Ill (D.J.W.); Texas Cardiac Arrhythmia Institute, St David's Medical Center, Austin (A.N.); University of Oklahoma, Oklahoma City (W.M.J., H.N.); Hospital of the University of Pennsylvania, Philadelphia (F.E.M.); Diagnostic Cardiology Group, Parkridge Medical Center, Chattanooga, Tenn (T.T.); Penn State Heart and Vascular Institute, Hershey (M.D.G.); Lancaster Heart Foundation, Lancaster, Pa (S.J.W.); Ohio State University Medical Center, Columbus (E.G.D.); Utah Valley Medical Center, Provo (C.H.); Henry Ford Hospital, Detroit, Mich (C.S.); Christ Hospital, Oak Lawn, Ill (T.E.B.); Bellin Memorial Hospital, Green Bay, Wis (M.J.); Central Baptist Hospital, Lexington, Ky (G.F.T.); and Piedmont Heart Institute, Atlanta, Ga (H.A.K.).

* To whom correspondence should be addressed. E-mail: wstevenson{at}partners.org.

Background—Recurrent ventricular tachycardia (VT) is an important cause of mortality and morbidity late after myocardial infarction. With frequent use of implantable cardioverter-defibrillators, these VTs are often poorly defined and not tolerated for mapping, factors previously viewed as relative contraindications to ablation. This observational multicenter study assessed the outcome of VT ablation with a saline-irrigated catheter combined with an electroanatomic mapping system.

Methods and Results—Two hundred thirty-one patients (median LV ejection fraction, 0.25; heart failure in 62%) with recurrent episodes of monomorphic VT (median, 11 in the preceding 6 months) caused by prior myocardial infarction were enrolled. All inducible monomorphic VTs with a rate approximating or slower than any spontaneous VTs were targeted for ablation guided by electroanatomic mapping during sinus rhythm and/or VT. Patients were not excluded for multiple VTs (median, 3 per patient) or unmappable VT (present in 69% of patients). Ablation abolished all inducible VTs in 49% of patients. The primary end point of freedom from recurrent incessant VT or intermittent VT after 6 months of follow-up was achieved for 123 patients (53%). In 142 patients with implantable cardioverter-defibrillators before and after ablation for intermittent VT who survived 6 months, VT episodes were reduced from a median of 11.5 to 0 (P<0.0001). The 1-year mortality rate was 18%, with 72.5% of deaths attributed to ventricular arrhythmias or heart failure. The procedure mortality rate was 3%, with no strokes.

Conclusions—Catheter ablation is a reasonable option to reduce episodes of recurrent VT in patients with prior myocardial infarction, even when multiple and/or unmappable VTs are present. This population remains at high risk for death, warranting surveillance and further study.


Key words: ablation • electrophysiology • mapping • myocardial infarction • tachyarrhythmias


Related Article:

Clinical Summaries
Circulation 2008 118: 2667-2668. [Extract] [Full Text]



This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
K. Shivkumar and R. Tung
Improving our understanding of epicardial ventricular tachycardia in nonischemic cardiomyopathy.
J. Am. Coll. Cardiol., August 25, 2009; 54(9): 809 - 811.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. M. Haqqani, J. M. Kalman, K. C. Roberts-Thomson, R. N. Balasubramaniam, R. Rosso, R. L. Snowdon, P. B. Sparks, J. K. Vohra, and J. B. Morton
Fundamental Differences in Electrophysiologic and Electroanatomic Substrate Between Ischemic Cardiomyopathy Patients With and Without Clinical Ventricular Tachycardia
J. Am. Coll. Cardiol., July 7, 2009; 54(2): 166 - 173.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
E. M. Aliot, W. G. Stevenson, J. M. Almendral-Garrote, F. Bogun, C. H. Calkins, E. Delacretaz, P. D. Bella, G. Hindricks, P. Jais, M. E. Josephson, et al.
EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: Developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA)
Europace, June 1, 2009; 11(6): 771 - 817.
[Full Text] [PDF]